Enteris, Cara Therapeutics Enter Peptelligence Pact

Enteris BioPharma, Inc., a biotechnology company, has entered a definitive licensing agreement with Cara Therapeutics for Enteris' Peptelligencetechnology in the ongoing development of an oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin, KORSUVA. Peptelligence is Enteris' platform for the oral delivery of peptides and BCS class II, III and IV small molecules.

The oral tablet formulation of KORSUVA (Oral KORSUVA) was engineered using Peptelligence, and is currently in three separate Phase II trials for pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC), stage III-V chronic kidney disease (CKD), and atopic dermatitis (AD). This agreement will allow Cara to continue its Oral KORSUVA programs into Phase III and beyond.

Under the terms, Cara Therapeutics has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA worldwide, excluding Japan and South Korea. In exchange, Enteris will receive an upfront payment of $8 million, with 50% payable in cash and 50% payable in shares of Cara's common stock. Cara will also pay Enteris milestone payments upon the achievement of certain development, regulatory and commercial milestones and royalties based on sales in the licensed territory. Cara retains the right to buy-out the royalty obligation for a period of two years under prespecified conditions.

"This is a watershed moment for Enteris and our Peptelligence® platform, and we greatly welcome the opportunity to deepen our relationship with Cara Therapeutics in the ongoing development of its Oral Korsuva™ pipeline," said Joel Tune, CEO of Enteris BioPharma. "The ability of our Peptelligence® platform to enable the oral delivery of peptide therapeutics, such as CR845/difelikefalin, is a potential game-changer for numerous peptide and small molecule-based drugs in development and on the market given the convenience and marketability of an orally administered tablet in comparison to an injection."

"We are pleased to formalize our ongoing work with Enteris and look forward to the continued advance of our Oral KORSUVA™ program, which now includes three Phase 2 clinical trials in pruritus settings," stated Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "Effective treatment of pruritus remains a significant unmet need in patients with atopic dermatitis, liver disease and chronic kidney disease, adding to their discomfort and seriously impacting patients' quality of life, including sleep disruption, altered eating habits, anxiety and depression. We believe that KORSUVA may provide a potential, first-in-class therapeutic to treat pruritus across clinical populations, and the ability to deliver it via an oral tablet formulation expands patient accessibility to the benefits of the product, if approved."

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.